COMBINATION THERAPY OF A CARRIER AND A

• Main Authors: NAUGH, JAMES, A, CARLSON ERIC C
• Format: Patent
• Language: Chinese; English
• Published: 05.01.2024
• Subjects: HUMAN NECESSITIES; HYGIENE; MEDICAL OR VETERINARY SCIENCE; PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES

The present invention provides methods of increasing the bioavailability and/or efficacy of a therapeutic agent in the treatment of ocular surface, corneal, or anterior chamber conditions. In particular, tear production is increased by administering an electrical stimulus, an ultrasonic stimulus, and/or a drug such as an nAChR [alpha] 7 agonist (e.g., varenicline, (R)-5-((E)-2-pyrrolidin-3-yl vinyl) pyrimidine, 5-{(E)-2-[(3R)-pyrrolidin-3-yl] vinyl} pyrimidine, or (R, E)-5-((2-pyrrolidin-3-yl) vinyl) pyrimidine). The provided primary therapeutic agents include recombinant adeno-associated virus (AAV) vectors that express therapeutic gene products (e.g., biological drugs). Methods of use of the related compositions are also provided. 本发明提供增加治疗剂治疗眼表面病症、角膜病症或前房病症的生物可用性和/或功效的方法。特别地，通过施用电刺激、超声波刺激和/或诸如nAChRα7激动剂(例如，伐尼克兰、(R)-5-((E)-2-吡咯烷-3-基乙烯基)嘧啶、5-{(E)-2-[(3R)-吡咯烷-3-基]乙烯基}嘧啶、或(R,E)-5-((2-吡咯烷-3-基)乙烯基)嘧啶)等药物来增加泪液产生。所提供的主要治疗剂包括表达治疗性基因产物(例如，生物药物)的重组腺相关病毒(AAV)载体。还提供相关组合物的使用方法。